Want to see EVFM full AI Analyst Report?
EVFM Stock Chart & Stats
$0.01
<$0.01(17.07%)
At close: 4:00 PM EDT
$0.01
<$0.01(17.07%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.02
Previous CloseN/A
Volume404.53K
Average Volume (3M)589.38K
Market Cap
$927.71K
Enterprise Value$56.17
Total Cash (Recent Filing)$2.38M
Total Debt (Recent Filing)$52.46M
Price to Earnings (P/E)―
Beta-0.12
Next Earnings
Aug 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding132,530,080
10 Day Avg. Volume412,838
30 Day Avg. Volume589,380
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)-0.02
Price to Sales (P/S)0.06
P/FCF Ratio-0.59
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)57.5
Revenue Forecast (FY)$241.13M
Bulls Say, Bears Say
Bulls Say
High Gross MarginA sustained ~75% gross margin indicates strong unit economics for Evofem’s marketed products. Durable product-level profitability gives the company leverage to reach operating breakeven if SG&A is reduced or sales scale, supporting long-term margin recovery and reinvestment capacity.
Africa Solosec Distribution DealA five-year exclusive distribution pact opens a structurally large addressable market with endemic BV/trichomoniasis. This partnership creates multi-year, non-dilutive revenue potential and regional commercialization capability that can diversify and stabilize revenue beyond U.S. Phexxi sales.
Commercialization & Partnership ExecutionManagement has demonstrated ability to secure international alliances and broaden commercial footprint. Sustained execution of distribution partnerships supports recurring prescription sales, reduces single-market dependency, and can provide predictable, non-dilutive cash flows over the medium term.
Bears Say
Highly Stressed Balance SheetDeeply negative equity and outsized debt versus a tiny asset base materially weaken financial flexibility. Over months this impairs ability to absorb shocks, limits access to favorable capital, and raises the probability of dilutive financing or restructuring if operating cash flow does not reliably improve.
Weak Cash GenerationPersistently negative operating and free cash flow means the company consumes cash to support operations. Without consistent positive cash generation, Evofem must rely on financing to fund commercialization and international expansion, increasing dilution and constraining long-term investment in growth.
Costly, Restrictive FinancingHigh-cost debt with tight covenants restricts M&A, asset sales and strategic moves while amplifying cash interest burden. Such financing reduces operational freedom and can force near-term cash priorities, undermining the company's ability to scale commercialization or invest in durable growth initiatives.
Evofem Biosciences News
EVFM FAQ
What was Evofem Biosciences’s price range in the past 12 months?
Evofem Biosciences lowest stock price was <$0.01 and its highest was $0.02 in the past 12 months.
What is Evofem Biosciences’s market cap?
Evofem Biosciences’s market cap is $927.71K.
When is Evofem Biosciences’s upcoming earnings report date?
Evofem Biosciences’s upcoming earnings report date is Aug 19, 2026 which is in 12 days.
How were Evofem Biosciences’s earnings last quarter?
Evofem Biosciences released its earnings results on May 18, 2026. The company reported -$0.041 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Evofem Biosciences overvalued?
According to Wall Street analysts Evofem Biosciences’s price is currently Overvalued.
Does Evofem Biosciences pay dividends?
Evofem Biosciences does not currently pay dividends.
What is Evofem Biosciences’s EPS estimate?
Evofem Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Evofem Biosciences have?
Evofem Biosciences has 132,530,080 shares outstanding.
What happened to Evofem Biosciences’s price movement after its last earnings report?
Evofem Biosciences reported an EPS of -$0.041 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Evofem Biosciences?
Currently, no hedge funds are holding shares in EVFM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Evofem Biosciences
Evofem Biosciences, Inc. operates as a biopharmaceutical enterprise dedicated to innovating and bringing to market treatments that address critical underserved areas in women's sexual and reproductive health. Their leading commercial offering is Phexxi, a vaginal gel specifically designed as a contraceptive. Additionally, the company is actively advancing EVO100, an antimicrobial vaginal gel under development, intended to prevent the urogenital spread of both Chlamydia trachomatis and Neisseria gonorrhoeae infections in women. The company's main office is situated in San Diego, California.